|
| 37561058 | Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety. | Am J Gastroenterol | 2024 |
| 36929625 | Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19. | Clin Transl Sci | 2023 |
| 37466213 | Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1). | J Infect Dis | 2023 |
| 34864948 | Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. | Clin Infect Dis | 2022 |
| 35532238 | Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. | Antimicrob Agents Chemother | 2022 |
| 36039098 | Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection. | Open Forum Infect Dis | 2022 |
| 35248213 | Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial. | Lancet Gastroenterol Hepatol | 2022 |
| 35248212 | Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. | Lancet Gastroenterol Hepatol | 2022 |
| 34937145 | Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. | N Engl J Med | 2022 |
| 34221918 | 3-year Treatment of Tenofovir Alafenamide <i>vs</i>. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China. | J Clin Transl Hepatol | 2021 |
| 32580966 | Correction for Han et al., "<i>In Vitro</i> Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir". | J Clin Microbiol | 2020 |
| 30552056 | Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. | Lancet Gastroenterol Hepatol | 2019 |
| 30790229 | Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. | Hepatol Int | 2019 |
| 29091342 | Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. | Liver Int | 2018 |
| 29886154 | Sofosbuvir/velpatasvir for 12⿯weeks in genotype 1-4 HCV-infected liver transplant recipients. | J Hepatol | 2018 |
| 30098373 | No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12⿯weeks in HCV DAA-experienced patients. | J Hepatol | 2018 |
| 29958855 | Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. | Gastroenterology | 2018 |
| 30030720 | Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. | Hepatol Int | 2018 |
| 29637511 | Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. | Hepatol Int | 2018 |
| 29175627 | Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems. | Virology | 2018 |
| 28984067 | Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. | J Viral Hepat | 2018 |
| 29174546 | Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. | Gastroenterology | 2018 |
| 28343981 | Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. | J Hepatol | 2017 |
| 28494238 | SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency. | Cell Host Microbe | 2017 |
| 25381252 | The hepatitis C virus core protein inhibits adipose triglyceride lipase (ATGL)-mediated lipid mobilization and enhances the ATGL interaction with comparative gene identification 58 (CGI-58) and lipid droplets. | J Biol Chem | 2014 |
| 23420847 | Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core. | J Biol Chem | 2013 |
| 24099293 | Lipid droplets and viral infections. | Methods Cell Biol | 2013 |
| 23593007 | Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein. | PLoS Pathog | 2013 |
| 23744144 | How the antiviral immune response boosts liver fat. | Nat Med | 2013 |
| 22072966 | Rab7A is required for efficient production of infectious HIV-1. | PLoS Pathog | 2011 |
| 19451649 | Endosomal trafficking of HIV-1 gag and genomic RNAs regulates viral egress. | J Biol Chem | 2009 |
| 17538020 | The clathrin adaptor complex AP-1 binds HIV-1 and MLV Gag and facilitates their budding. | Mol Biol Cell | 2007 |
| 17003132 | Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. | Proc Natl Acad Sci U S A | 2006 |